Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-06

Study Completion Date

2015-11-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.

NCT02616770

Asthma

COMPLETED PHASE1

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189

Healthy Asthma

TERMINATED PHASE1

Investigation of Lung Ventilation Inhomogeneity in Pediatric Asthma

NCT01095354

Asthma

COMPLETED

The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

NCT01225549

Asthma

COMPLETED PHASE2

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

NCT02753764

Corticosteroid Resistant (CR) Asthmatics

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase IIa, placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%) administered by nebulization in subjects with mild atopic asthma

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

S1226 (8%)

The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.

Group Type ACTIVE_COMPARATOR

S1226(8%)

Intervention Type DRUG

The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.

Placebo

The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

S1226(8%)

The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.

Intervention Type DRUG

Placebo

Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PFOB nebulized with 8% CO2 in medical gas mixture normal saline nebulized with compressed medical air

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female subjects 18-40 years of age.
2. BMI of 18-40 kg/m2
3. Subject is not currently on topical or systemic corticosteroids and has not taken any oral/injectable corticosteroid within 60 days prior to study drug administration and has not used any inhaled/nasal corticosteroid within 30 days prior to study drug administration.
4. Female subjects must not be pregnant or lactating and must be practicing an acceptable method of birth control, or be surgically sterile or postmenopausal.
5. Subjects must have had asthma for at least 3 months.
6. Subject is a non-smoker or has not smoked for \> 1year and has \< 10 pack-year history.
7. Subject has a methacholine PC20 of less than 16mg/mL.
8. Subject has normal laboratory values (normal values as clinically judged by the Investigator) for clinical chemistry, hematology, and urinalysis.
9. Subject is in general good health based on medical history and clinically acceptable results for the following assessments: physical examination, vital signs, and 12-lead ECG, as assessed by study physicians.
10. Subject is able to communicate effectively with study personnel and is reliable, willing and cooperative in terms of compliance with protocol.

Exclusion Criteria

Subjects to whom any of the following applies will be excluded from the study:

1. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.
2. Subjects who require inhaled β2-agonist medication more frequently than 4 times a week (other than prophylactically prior to exercise) during the 4 week period before screening.
3. Subjects who are currently treated with any asthma medication other than inhaled β2-agonist.
4. Subjects with frequent emergency room visits for asthma, with prior ICU admission or those with prior intubation.
5. Presence or history of neurologic, endocrine, hepatic, gastrointestinal or kidney disease or therapy that would jeopardize the subject's well-being by participating in the study.
6. Cardiovascular disease that, in the opinion of the Investigator, is not stable or could put the subject at increased risk by participating in the study.
7. Any reason which, in the opinion of the Investigator (or delegate), would prevent the subject from participating in the study.
8. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
9. Subject has a history of physician diagnosed panic disorder or other anxiety disorders.
10. Subject is currently receiving treatment, or has received treatment in the previous 14 days, with monoamine oxidase (MAO) inhibitors.
11. Subjects dosed with an investigational drug within 30 days prior to the Screening Visit.
12. Subjects dosed with biologic therapy within the previous 4 months or 5 half-lives from baseline methacholine testing.
13. Subject has current (or within the last six months) evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit)
14. Positive urine drug screen or urine cotinine test at screening.
15. Breast-feeding subject.
16. Positive pregnancy test at screening.
17. Subject, who in the opinion of the Investigator, is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No